|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
AngioScore, Inc. Announces 510(k) Clearance to Market AngioSculpt Scoring Balloon Catheter for Renal Indications
3/26/2010 7:12:38 AM
FREMONT, Calif.--(BUSINESS WIRE)--AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its AngioSculpt® PTA Scoring Balloon Catheter for dilatation of lesions in renal arteries.
AngioScore previously had received 510(k) clearance to market the AngioSculpt device for dilatation of lesions in the iliac, femoral, ilio-femoral, popliteal and infra-popliteal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This new 510(k) clearance adds renal arteries to the indications for use statement.
According to Gary Gershony, M.D., AngioScore’s Chief Medical Officer, the AngioSculpt may be particularly useful in treating renal artery stenotic disease, which is often associated with medically refractory hypertension or a serious deterioration in kidney function: “Due to the frequency of significant calcification and the ostial location of these lesions, renal arteries present a unique challenge for the interventional physician caring for these patients.
“The design of the AngioSculpt is particularly useful in treating resistant fibro-calcific lesions and permitting precise device deployment in the ostial location by avoiding slippage. The AngioSculpt should prove to be a very welcome addition to the armamentarium of physicians treating renal artery stenosis,” said Dr. Gershony.
“We are very pleased to have received this important 510(k) clearance,” said Thomas R. Trotter, President and CEO of AngioScore. “Sales of AngioSculpt devices for the treatment of Peripheral Artery Disease (PAD) have been growing rapidly, and the opportunity to now include renal arteries is a major positive development for the company. PAD is one of the fastest-growing segments of the Endovascular Market, with over two million annual procedures worldwide, including an estimated 300,000 renal interventions."
The AngioSculpt Scoring Balloon Catheter represents the next generation in angioplasty catheters. Its innovative nitinol scoring element provides unique anti-slipping properties while circumferentially dilating plaque, providing a precise and predictable dilatation across a wide range of lesion types. The AngioSculpt provides the versatility and effectiveness of a new technology together with the simplicity and deliverability of a high-performance balloon catheter.
About AngioScore
AngioScore, Inc. (www.angioscore.com) is a privately funded endovascular company located in Fremont, California. AngioScore can be contacted at (510) 933-7900 or info@angioscore.com.
Note: This press release contains forward-looking statements that are based upon management’s current expectations and are inherently uncertain. Actual results and timing of events could differ materially from current expectations and forward-looking statements.
|
|
|
|
|
|
|
|
|
|
|